HALOZYME THERAPEUTICS, INC. Current Assets
HALOZYME THERAPEUTICS, INC. (HALO) had Current Assets of $933.02 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AssetsCurrent · last filed 2026-08-06
- 2026-06-30: Assets, Current $933.02M.
- 2026-03-31: Assets, Current $1.00B.
- 2025-12-31: Assets, Current $825.21M.
- 2025-09-30: Assets, Current $1.33B.
| Period end | Assets, Current | Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $933.02M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $1.00B 10-Q · filed 2026-05-11 | |
| 2025-12-31 | $825.21M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $1.33B 10-Q · filed 2025-11-03 | |
| 2025-06-30 | $1.12B 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $1.26B 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $1.09B 10-K · filed 2026-02-17 | |
| 2024-09-30 | $1.13B 10-Q · filed 2024-10-31 | |
| 2024-06-30 | $987.80M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $873.58M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $746.42M 10-K · filed 2025-02-18 | |
| 2023-09-30 | $879.01M 10-Q · filed 2023-11-06 | |
| 2023-06-30 | $765.75M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $615.02M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $739.01M 10-K · filed 2024-02-20 | |
| 2022-09-30 | $653.20M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $541.94M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $988.69M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $926.29M 10-K · filed 2023-02-21 | |
| 2021-09-30 | $1.02B 10-Q · filed 2021-11-02 | |
| 2021-06-30 | $999.75M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $941.72M 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $554.76M 10-K · filed 2022-02-22 | |
| 2020-09-30 | $498.89M 10-Q · filed 2020-11-02 | |
| 2020-06-30 | $500.36M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $467.97M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $543.44M 10-K · filed 2021-02-23 | |
| 2019-09-30 | $342.04M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $391.71M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $409.04M 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $427.85M 10-K · filed 2020-02-24 | |
| 2018-09-30 | $429.93M 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $462.03M 10-Q · filed 2018-08-07 | |
| 2018-03-31 | $484.47M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $510.37M 10-K · filed 2019-02-21 | |
| 2017-09-30 | $353.35M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $340.83M 10-Q · filed 2017-08-08 | |
| 2017-03-31 | $222.35M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $256.53M 10-K · filed 2018-02-20 | |
| 2016-09-30 | $272.61M 10-Q · filed 2016-11-07 | |
| 2016-06-30 | $284.34M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $297.04M 10-Q · filed 2016-05-09 | |
| 2015-12-31 | $171.77M 10-K · filed 2017-02-28 | |
| 2015-09-30 | $153.09M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $168.44M 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $153.33M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $161.32M 10-K · filed 2016-02-29 | |
| 2014-09-30 | $158.60M 10-Q · filed 2014-11-10 | |
| 2014-06-30 | $175.62M 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $190.91M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $95.19M 10-K · filed 2015-03-02 | $95.20M 10-K · filed 2014-02-28 |
| 2013-09-30 | $102.82M 10-Q · filed 2013-11-08 | |
| 2013-06-30 | $100.42M 10-Q · filed 2013-08-07 | |
| 2013-03-31 | $111.11M 10-Q · filed 2013-05-08 | |
| 2012-12-31 | $130.63M 10-K · filed 2014-02-28 | $131.03M 10-K · filed 2013-03-01 |
| 2012-09-30 | $105.62M 10-Q · filed 2012-11-08 | |
| 2012-06-30 | $119.73M 10-Q · filed 2012-08-09 | |
| 2012-03-31 | $132.57M 10-Q · filed 2012-05-07 | |
| 2011-12-31 | $63.99M 10-K · filed 2013-03-01 | |
| 2011-09-30 | $76.97M 10-Q · filed 2011-11-08 | |
| 2011-06-30 | $88.01M 10-Q · filed 2011-08-05 | |
| 2010-12-31 | $89.50M 10-K · filed 2012-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |